文献速递肿瘤 PET/CT核素与放射性配体治疗

用89Zr-草酸标记过继转移的嵌合抗原受体T细胞并进行PET成像

PET of Adoptively Transferred Chimeric Antigen Receptor T Cells with 89Zr-Oxine.
PubMed 文献 · J Nucl Med · 2018-05-04

该研究优化了89Zr-草酸标记CAR T细胞的条件,并在两种小鼠异种移植肿瘤模型中评估PET成像过继转移CAR T细胞的可行性。标记效率为75%,6天内保留超过60%的89Zr;以70 kBq/10^6细胞标记时,体外细胞因子产生、迁移、肿瘤细胞毒性和体内抗肿瘤活性均未显著降低。结论认为89Zr-草酸是可用于实时评估细胞疗法的临床可转化平台。

要点

  • CAR T细胞标记效率为75%,6天内保留超过60%的89Zr。
  • 以70 kBq/10^6细胞标记时,体外功能及体内抗肿瘤活性未显著降低。
  • IL13Rα2-CAR T细胞经脑室内递送后,PET可在中枢神经系统和颅内肿瘤内检测到至少6天。

核心结论

  • 89Zr-草酸可用于标记和成像CAR T细胞,同时维持细胞活力和功能。
  • 基于这些研究,作者认为89Zr-草酸是可用于实时评估细胞疗法的临床可转化平台。

研究设计与样本

  • 研究优化了每10^6个CAR T细胞使用0-1.4 MBq的89Zr-草酸进行标记的条件。
  • 在两种小鼠异种移植肿瘤模型中评估了89Zr-草酸标记的CAR T细胞的体内分布:颅内递送IL13Rα2靶向CAR T细胞的胶质母细胞瘤脑肿瘤模型,以及静脉递送前列腺干细胞抗原(PSCA)靶向CAR T细胞的皮下前列腺肿瘤模型。

主要发现

  • CAR T细胞被高效标记(75%),并在6天内保留超过60%的89Zr。
  • 以70 kBq/10^6细胞标记时,体外细胞因子产生、迁移和肿瘤细胞毒性,以及体内抗肿瘤活性均未显著降低。
  • 经脑室内递送的IL13Rα2-CAR T细胞在中枢神经系统和颅内肿瘤内可被PET检测到至少6天。
  • 静脉给予的PSCA-CAR T细胞也显示出肿瘤趋向性,肿瘤与肌肉比值比CAR阴性T细胞高9倍。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor (CAR) T cell therapy is a promising clinical approach for reducing tumor progression and prolonging patient survival. However, improvements in both the safety and the potency of CAR T cell therapy demand quantitative imaging techniques to determine the distribution of cells after adoptive transfer. The purpose of this study was to optimize 89Zr-oxine labeling of CAR T cells and evaluate PET as a platform for imaging adoptively transferred CAR T cells. Methods: CAR T cells were labeled with 0-1.4 MBq of 89Zr-oxine per 106 cells and assessed for radioactivity retention, viability, and functionality. In vivo trafficking of 89Zr-oxine-labeled CAR T cells was evaluated in 2 murine xenograft tumor models: glioblastoma brain tumors with intracranially delivered IL13Rα2-targeted CAR T cells, and subcutaneous prostate tumors with intravenously delivered prostate stem cell antigen (PSCA)-targeted CAR T cells. Results: CAR T cells were efficiently labeled (75%) and retained more than 60% of the 89Zr over 6 d. In vitro cytokine production, migration, and tumor cytotoxicity, as well as in vivo antitumor activity, were not significantly reduced when labeled with 70 kBq/106 cells. IL13Rα2-CAR T cells delivered intraventricularly were detectable by PET for at least 6 d throughout the central nervous system and within intracranial tumors. When intravenously administered, PSCA-CAR T cells also showed tumor tropism, with a 9-fold greater tumor-to-muscle ratio than for CAR-negative T cells. Conclusion:89Zr-oxine can be used for labeling and imaging CAR T cells while maintaining cell viability and function. On the basis of these studies, we conclude that 89Zr-oxine is a clinically translatable platform for real-time assessment of cell therapies.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Weist MR, Starr R, Aguilar B, et al. PET of Adoptively Transferred Chimeric Antigen Receptor T Cells with 89Zr-Oxine. J Nucl Med. 2018. PMID: 29728514. doi:10.2967/jnumed.117.206714

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。